Back
Organon & Co (OGN)
PharmaceuticalsOGN · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$13.81
+0.44%Weekly undervalued picks (like OGN)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$0.72
ROE
34.0%
Gross margin
53.8%
Debt/Equity
9.49x
Revenue growth
-3.5%
Organon & Co — company intelligence
Earnings surprises
Q2 2026$0.85 vs $0.93 est-8.3%
Q1 2026$0.71 vs $0.84 est-15.2%
Q4 2025$0.63 vs $0.73 est-14.2%
Q3 2025$1.01 vs $0.95 est+6.8%
Analyst consensus · 13 analysts
0 Buy7 Hold6 Sell
Updated Oct 9, 2026
Insider activity · 90 days
0 buys2 sellsnet -18,895 shares
Arjona Ferreira Juan CamiloSell 4,134 · Aug 11, 2026
Arjona Ferreira Juan Camiloother 11,519 · Aug 11, 2026
Drinane Juliana PapaSell 14,761 · Aug 5, 2026
Recent SEC filings
4 — Insider transaction reportAug 12, 2026
4 — Insider transaction reportAug 5, 2026
8-K — Material event reportJul 31, 2026
Latest news
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference — Yahoo · 1w ago
Organon Canada Announces Availability Of NDUVRA To Treat Moderate To Severe Atopic Dermatitis — Benzinga · 1w ago
Why Organon (OGN) Is Getting Attention Today — Yahoo · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like OGN)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.